Upfront Surgery and Surgery Following Neoadjuvant Treatment of Pancreatic Ductal Adenocarcinoma: A Comparative Analysis of Short-term Postoperative Outcomes

JI HYE JUNG, SO KYUNG YOON, SO JEONG YOON, SANG HYUN SHIN, IN WOONG HAN and JIN SEOK HEO

Division of Hepatobiliary-Pancreatic Surgery, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea

Abstract. Background/Aim: In cases where neoadjuvant treatment (NAT) is administered, research on short-term postoperative outcomes appears to be insufficient. We compared short-term outcomes of upfront surgery (UpS) cases and NAT cases for pancreatic ductal adenocarcinoma (PDAC). Patients and Methods: We retrospectively reviewed 1,228 cases that had elective pancreatectomy at Samsung Medical Center from 2010 to 2020. All cases were classified into resectable pancreatic cancer (RPC) and locally advanced pancreatic cancer (LAPC) according to NCCN guidelines 2017. In each group, factors were compared between the UpS and NAT groups. Results: Rate of vascular resection was higher in the NAT group in RPC, compared to that in the NAT group in LAPC. Short-term postoperative outcomes had no significant differences between the UpS and NAT groups in both RPC and LAPC. Conclusion: In the NAT group, there were no significant differences from UpS in terms of short-term postoperative outcomes. Conversion surgery following NAT is a favorable strategy.

Although recent studies show that the 5-year survival rates of pancreatic cancer have improved, they are still lower compared with other cancers (1, 2). In order to overcome poor outcomes, multidisciplinary evaluation and management have been performed together including surgery, oncology, radiation, radiological imaging, intervention, endoscopy, and pathology

Correspondence to: Jin Seok Heo, MD, Ph.D., Division of Hepatobiliary-Pancreatic Surgery, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. Tel: +82 234100262, Fax: +82 234106980, e-mail: jsheo@skku.edu

Key Words: Resectable pancreatic cancer, locally advanced pancreatic cancer, upfront surgery, neoadjuvant treatment, short-term postoperative outcomes.

(3, 4). Among these, radical resection of the primary cancer with lymphadenectomy is necessary (3, 5-7). Improvement in long-term and short-term postoperative outcomes achieved by radical resection has been reported in numerous studies for a long time (8-13). In addition, the concept of pancreatic cancer as a systemic disease has been widely accepted. Therefore, systemic therapy along with surgical resection have become important in order to improve outcomes (14-16). Thus, upfront surgery followed by adjuvant systemic therapy has become the standard approach to pancreatic cancer treatment and improved outcomes have also been reported in many studies (5, 17-20). Despite significant improvement in long-term outcomes including overall survival, this strategy of postoperative adjuvant therapy has been challenged, because the planned schedule of adjuvant therapy can be disrupted due to complications occurring after surgery. Furthermore, the neoadjuvant setting before surgery can help identify whether the tumor is biologically unfavorable and progress rapidly despite resection (5, 19, 21, 22). Above all, it is important that the neoadjuvant treatment (NAT) is helpful by increasing the likelihood and radicality of resection via downstaging of the tumor. Previous studies have shown that NAT offers substantial benefit in outcomes including survival for borderline resectable and unresectable pancreatic cancer (23-27). There have also been studies showing that NAT was effective for resectable pancreatic cancer as well (28-31).

The administration of systemic therapy before surgery has been sufficiently proposed as an alternative to postoperative adjuvant therapy, and has been increasingly performed. However, most studies that reported the effectiveness of NAT to date have analysed the long-term postoperative outcomes. The research on short-term postoperative outcomes appears to be insufficient. Therefore, we aimed to compare the shortterm postoperative outcomes of patients who underwent upfront surgery and those who underwent neoadjuvant treatment followed by surgery for pancreatic ductal adenocarcinoma (PDAC) in our high-volume single center.

Patients and Methods

Patients and data collection. We collected data of consecutive patients diagnosed with PDAC who underwent elective pancreatectomy including pylorus preserving pancreaticoduodenectomy (PPPD), pylorus resecting pancreaticoduodenectomy (PRPD), distal pancreatectomy (DP), and total pancreatectomy (TP) at Samsung Medical Center in Seoul, South Korea, from January 2010 to March 2020. In our center, the frequency of NAT has increased gradually since 2010, therefore the starting point of inclusion in this study was set to 2010. All cases of pancreatectomy performed with curative intent were included and cases with distant metastasis confirmed in preoperative evaluation were excluded. A total of 1,228 cases were included and analysed. Data were collected from electronic medical records of our center and reviewed retrospectively. This study was approved by the Institutional review board (IRB) of Samsung Medical Center to search the data of included patients (IRB number: 2020-09-092). Our IRB waived the need for written informed consent from patients because this study was retrospectively designed.

We reviewed the preoperative imaging examinations such as CT or MRI of all the patients to identify whether the major blood vessel was in contact with the tumor, and if so, the angle of contact. We determined resectability according to the National Comprehensive Cancer Network (NCCN) guidelines version 2017 (20). All cases were classified into three groups of resectable, borderline resectable, and unresectable pancreatic cancer. Borderline resectable and unresectable pancreatic cancer were collectively referred to as locally advanced pancreatic cancer. Thus, all the cases in this study were divided into the resectable pancreatic cancer (RPC) group and the locally advanced pancreatic cancer (LAPC) group.

Each of the RPC and the LAPC groups was divided further into two groups of upfront surgery (UpS group) and neoadjuvant treatment followed by surgery (NAT group). Many preoperative factors and postoperative factors including various complications were compared between the groups RPC and LAPC. The discrepancy in the number of patients between the UpS group and the NAT group was too large, therefore we conducted propensity score matching (PSM) analysis to extract balanced cases. For matching factors, several preoperative factors such as age, gender, body mass index (BMI), American society of anesthesiologist (ASA) score, diabetes mellitus (DM), and initial tumor size were used.

We thoroughly reviewed the electronic medical records to find whether major blood vessels invaded by the tumor were resected and whether other organs were resected together, which was distinct from vascular resection.

In order to analyze the pathological characteristics of each group, various information including stage was obtained. We commonly reset the stage of entire cohort according to the 8th American Joint Committee Cancer (AJCC) Staging System. T stage is determined only by the tumor size (32). Regarding resection margin, R0 indicates both grossly and microscopically margin-negative resection and R2 indicates the presence of residual tumor even grossly. The case of resected margin microscopically found within 1mm from the tumor is determined as R1 (33, 34).

In the short-term postoperative outcomes, the keyword of our study, the short-term refers to within 90 days after surgery. We investigated length of stay (hospitalization days), general complications, postoperative pancreatic fistula (POPF), unplanned readmission, and mortality. Readmission and mortality within 30 days after surgery were also searched. General complications were graded according to the Clavien-Dindo classification (35). Grades I and II were referred to as minor complications, and from IIIa, they were referred to as major complications that required special managements such as intervention, surgery, intensive care, and others (36). The POPF, a specific complication after pancreatectomy, was graded based on the criteria of the International Study Group of Pancreatic Surgery (ISGPS) updated in 2016 (37). POPF grades B and C were collectively referred to as clinically relevant POPF (CR-POPF), which required further management that differed from the expected postoperative pathway (38, 39).

Statistical analysis. All statistical analyses comparing clinical, operative, pathological characteristics, and short-term postoperative outcomes were conducted using the IBM SPSS statistical software, version 27 (Chicago, IL, USA). Continuous variables between the groups were compared using the independent *t*-test, and categorical data were analyzed with the chi-square test. Differences with a probability (*p*) value of 0.05 or less were considered statistically significant. As mentioned previously, we conducted PSM in order to balance the UpS group and the NAT group using several preoperative factors. We used the R statistical software version 4.0.0 to execute the PSM, and used the nearest neighbor matching method with caliper width 0.25 of the standard deviation of the logit of propensity score. To extract the PSM dataset, six variables including age, gender, BMI, DM, ASA score, and initial tumor size were applied.

Results

Clinical, operative, and pathological characteristics. Figure 1 shows the number of patients in each group. The entire cohort of 1,228 patients included 879 cases in the RPC group and 349 cases in the LAPC group. The most common cause of classification into the LAPC group was the greater than 180° contact between tumor and portal vein (PV) or superior mesenteric vein (SMV). The next highest proportion was the case of celiac axis or common hepatic artery invasion. In addition, there were cases of superior mesenteric artery (SMA)/SMV jejunal branch invasion, SMA invasion, inferior vena cava (IVC) invasion, and others. The UpS group and the NAT group included 859 and 20 patients in the RPC group, and 277 and 72 patients in the LAPC group, respectively. As a result of conducting PSM analysis, the balancing accuracy was the highest when matched in the ratio of 1:3 and 1:1, respectively. After PSM, 60 versus 20 patients in RPC and 68 versus 68 patients in LAPC were balanced in the UpS group and the NAT group, respectively.

The clinical, operative, and pathological characteristics and the short-term postoperative outcomes of each group before PSM are shown in Table I. In LAPC, patients in the UpS group were significantly older (63.4 years *versus* 60.1 years) and had significantly lower body weight (59.9 kg *versus* 62.7 kg) than those in the NAT group. The distribution of underlying DM patients in RPC was found to be significantly less in the UpS group (38.3%) and greater (65.0%) in the NAT group. In LAPC, the initial tumor size was significantly larger in the




Figure 1. The number of patients in study flow. PDAC: Pancreatic ductal adenocarcinoma; PSM: propensity score matching.

NAT group (3.1 cm versus 2.8 cm). This tendency was not significant in RPC. The rate of vascular resection was significantly higher in the NAT group compared with the UpS group (55.0% versus 6.6%) in RPC, whereas vascular resection was significantly less performed in the NAT group than in the UpS group (34.7% versus 67.1%) in LAPC. All of the patients who underwent combined operation were in the UpS group, and none of them was in the NAT group. The rate of combined operation was 7.9% in the UpS group of LAPC, which was significant compared with the NAT group of LAPC. The combined operation was mostly attributed to resection of adjacent organs. Operation duration in the NAT group was significantly longer than that in the UpS group in RPC (322.8 min versus 273.1 min), whereas it was not significantly different in LAPC. More oncologic benefits of NAT were found in LAPC when compared with RPC. T stage and N stage were decreased. The rate of R0 resection was higher (76.4% versus 67.5%) and the rate of lymphovascular/perineural invasion was lower (30.6% versus 63.5%/66.6% versus 95.3%) in the NAT group than in the UpS group.

Age, whether patients had underlying DM or not, and initial tumor size that showed significant differences before PSM, were balanced after PSM conducted using these factors. The results of PSM of the six factors are shown in Table II.

Table III shows the PSM results of clinical characteristics excluding the six PSM factors, operative characteristics, pathological characteristics, and short-term postoperative outcomes in each group. The tendency of the rate of vascular resection and combined operation was still similar after PSM. The oncologic benefits of NAT observed in LAPC compared with RPC were similar after PSM. T stage, N stage, and the rate of lymphovascular/perineural invasion were significantly lower in the NAT group of LAPC. The rate of R0 resection was still higher, but was not significant.

Short-term postoperative outcomes. The short-term postoperative outcomes showed no significant differences between the UpS

group and the NAT group in both RPC and LAPC. The outcomes before PSM are listed in Table I. The length of stay did not differ and was 12.5 days *versus* 11.6 days in RPC and 13.1 days *versus* 12.8 days in LAPC, respectively. Major complications and CR-POPF requiring special management in the immediate postoperative period were not at all frequent when NAT was administered first. The incidence of major complications was 19.2% *versus* 15.0% in RPC and 17.7% *versus* 16.7% in LAPC, and that of CR-POPF was 6.6% *versus* 5.3% in RPC and 3.5% *versus* 3.0% in LAPC. Both the readmission rates within 30-days and 90-days after surgery showed no significant differences between the UpS group and the NAT group, regardless of RPC or LAPC. Likewise, there were no differences in mortality both within 30-days and 90-days.

Table III shows that the results of all short-term postoperative outcomes were still similar even after PSM. When NAT was administered, regardless of the classification of patients into RPC or LAPC, no significant increase in complications was detected in the short-term postoperative period.

Discussion

It is widely accepted that pancreatic cancer is a systemic disease and systemic therapy is important (14-16). As a pancreatic cancer treatment strategy, most of the systemic therapies had been performed after resection (17-20). Then, the effectiveness of NAT emerged, and has been increasingly performed (23-31). This study showed that NAT has been increasingly practiced in our center and included patients who underwent pancreatectomy from January 2010 to March 2020. The frequency of NAT increased abruptly in 2017 and has been steadily increasing since then, even though the frequency of upfront pancreatectomy has been almost the same since around 2013.

In LAPC, it was revealed that there was a significant oncologic benefit from NAT such as downstaging, despite the

	RPC (n=879)			LAPC (n=349)		
	UpS group (n=859)	NAT group (n=20)	<i>p</i> -Value	UpS group (n=277)	NAT group (n=72)	<i>p</i> -Value
Age	64.8±10.0	63.7±8.2	0.618	63.4±9.8	60.1±10.0	0.012
Gender			0.361			0.577
Male	498 (58.0)	14 (70.0)		167 (60.3)	46 (63.9)	
Female	361 (42.0)	6 (30.0)		110 (39.7)	26 (36.1)	
Body weight (kg)	60.8±9.9	62.2±10.1	0.541	59.9±9.5	62.7±10.0	0.026
BMI (kg/m ²)	23.2±3.1	23.1±2.8	0.871	22.7±2.8	23.4±3.0	0.094
DM			0.020			0.248
No	530 (61.7)	7 (35.0)		168 (60.6)	49 (68.1)	
Yes	329 (38.3)	13 (65.0)		109 (39.4)	23 (31.9)	
ASA score		()	1.000			0.159
1	110 (12.8)	2 (10.0)	11000	41 (14.8)	5 (7.0)	01107
2	657 (76.5)	16 (80.0)		207 (74.7)	61 (84.7)	
3	92 (10.7)	2 (10.0)		29 (10.5)	6 (8.3)	
Preoperative CEA	<i>J2</i> (10.7)	2 (10.0)	0.315	2) (10.5)	0 (0.5)	0.922
Normal (≤5 ng/ml)	628 (73.1)	15 (75.0)	0.515	206 (74.4)	52 (72.2)	0.922
Elevated (>5 ng/ml)	103 (12.0)			200 (74.4) 27 (9.7)	. ,	
		4 (20.0)		· · ·	8 (11.1)	
Unknown	128 (14.9)	1 (5.0)	0.416	44 (15.9)	12 (16.7)	0.072
Preoperative CA19-9	202 (24.0)	4 (20.0)	0.416	(0, (0,1,0))	26 (26.1)	0.072
Normal (≤37 U/ml)	292 (34.0)	4 (20.0)		69 (24.9)	26 (36.1)	
Elevated (>37 U/ml)	546 (63.6)	16 (80.0)		200 (72.2)	46 (63.9)	
Unknown	21 (2.4)	0 (0.0)		8 (2.9)	0 (0.0)	
Initial tumor size (cm)	2.7±1.2	3.2±0.7	0.057	2.8±0.9	3.1±0.9	0.010
Operation type			0.468			0.258
PPPD	266 (31.0)	9 (45.0)		106 (38.3)	23 (31.9)	
PRPD	222 (25.8)	5 (25.0)		109 (39.3)	27 (37.5)	
DP	328 (38.2)	5 (25.0)		39 (14.1)	17 (23.7)	
TP	43 (5.0)	1 (5.0)		23 (8.3)	5 (6.9)	
Vascular resection			<0.001			<0.001
No	802 (93.4)	9 (45.0)		91 (32.9)	47 (65.3)	
Yes	57 (6.6)	11 (55.0)		186 (67.1)	25 (34.7)	
Combined operation			0.096			0.011
No	747 (87.0)	20 (100.0)		255 (92.1)	72 (100.0)	
Yes	112 (13.0)	0 (0.0)		22 (7.9)	0 (0.0)	
Operation duration (minutes)	273.1±83.4	322.8±72.2	0.008	348.0±83.9	349.4±100.6	0.899
EBL (ml)	384.4±356.2	1027.5±2202.4	0.207	584.5±627.4	601.4±685.7	0.842
Differentiation			0.299			0.247
Well	52 (6.1)	1 (5.0)		11 (4.0)	3 (4.1)	
Moderately	564 (65.7)	17 (85.0)		186 (67.1)	49 (68.1)	
Poorly	189 (22.0)	1 (5.0)		73 (26.4)	15 (20.8)	
Undifferentiated	21 (2.4)	0 (0.0)		3 (1.1)	1 (1.4)	
Unknown	33 (3.8)	1 (5.0)		4 (1.4)	4 (5.6)	
Tumor size	3.0±1.6	2.8±1.0	0.621	3.2±1.3	2.3 ± 1.2	<0.001
T stage	5.011.0	2.011.0	0.334	5.211.5	2.3±1.2	<0.001
Tis	1 (0 1)	0 (0 0)	0.554	0 (0.0)	0 (0 0)	<0.001
	1(0.1)	0 (0.0)			0(0.0)	
Tla Tlb	3 (0.4)	0(0.0)		1 (0.4)	6 (8.3) 4 (5.6)	
T1b	7 (0.8)	1 (5.0)		0(0.0)	4 (5.6)	
T1c	192 (22.4)	3 (15.0)		31 (11.2)	18 (25.0)	
T2	532 (61.9)	13 (65.0)		199 (71.8)	40 (55.5)	
T3	124 (14.4)	3 (15.0)	A · · · ·	46 (16.6)	4 (5.6)	0.001
N stage			0.461			<0.001
NO	355 (41.3)	11 (55.0)		77 (27.8)	50 (69.4)	
N1	339 (39.5)	7 (35.0)		134 (48.4)	18 (25.0)	
N2	165 (19.2)	2 (10.0)		66 (23.8)	4 (5.6)	
Harvested LN	18.7±10.7	18.9±10.5	0.964	21.6±10.9	16.7±8.2	<0.001
Metastatic LN	2.0±3.0	1.4±3.2	0.397	2.7±3.7	0.7±1.8	<0.001

Table I. Clinical, operative, pathological characteristics and short-term postoperative outcomes [Mean±Standard deviation/number (percent)].

Table I. Continued

	RPC (n=879)			LAPC (n=349)		
	UpS group (n=859)	NAT group (n=20)	<i>p</i> -Value	UpS group (n=277)	NAT group (n=72)	<i>p</i> -Value
M stage			1.000			1.000
MO	848 (98.7)	20 (100.0)		275 (99.3)	72 (100.0)	
M1	11 (1.3)	0 (0.0)		2 (0.7)	0 (0.0)	
Resection margin			0.820			0.003
R0	691 (80.4)	16 (80.0)		187 (67.5)	55 (76.4)	
R1	159 (18.5)	4 (20.0)		86 (31.1)	12 (16.7)	
R2	9 (1.1)	0 (0.0)		4 (1.4)	5 (6.9)	
Lymphovascular invasion			0.733			< 0.001
No	308 (35.9)	9 (45.0)		76 (27.4)	44 (61.1)	
Yes	438 (50.9)	9 (45.0)		176 (63.5)	22 (30.6)	
Unknown	113 (13.2)	2 (10.0)		25 (9.1)	6 (8.3)	
Perineural invasion			1.000			< 0.001
No	88 (10.2)	2 (10.0)		10 (3.6)	21 (29.2)	
Yes	737 (85.8)	18 (90.0)		264 (95.3)	48 (66.6)	
Unknown	34 (4.0)	0 (0.0)		3 (1.1)	3 (4.2)	
Length of stay (days)	12.5±9.3	11.6±4.9	0.666	13.1±7.9	12.8±8.3	0.827
Clavien-Dindo classification			0.794			0.132
No complication	472 (54.9)	11 (55.0)		139 (50.2)	40 (55.6)	
Minor						
Ι	53 (6.2)	2 (10.0)		25 (9.0)	6 (8.3)	
II	169 (19.7)	4 (20.0)		64 (23.1)	14 (19.4)	
Major						
IIIa	119 (13.9)	2 (10.0)		37 (13.3)	7 (9.7)	
IIIb	19 (2.2)	1 (5.0)		1 (0.4)	4 (5.6)	
IVa	18 (2.1)	0 (0.0)		6 (2.2)	1 (1.4)	
IVb	2 (0.2)	0 (0.0)		1 (0.4)	0 (0.0)	
V	7 (0.8)	0 (0.0)		4 (1.4)	0 (0.0)	
POPF	n=816	n=19	1.000	n=254	n=67	1.000
No (biochemical leak) CR-POPF	762 (93.4)	18 (94.7)		245 (96.5)	65 (97.0)	
Grade B	49 (6.0)	1 (5.3)		7 (2.7)	2 (3.0)	
Grade C		0 (0.0)				
TP	5 (0.6) 43	0 (0.0)		2 (0.8) 23	0 (0.0) 5	
30-day unplanned readmission	43 62 (7.2)	1 (5.0)	1.000	13 (4.7)	5 (6.9)	0.548
90-day unplanned readmission	100 (11.6)	1 (5.0)	0.719	24 (8.7)	8 (11.1)	0.348
30-day mortality	4 (0.5)	1(5.0) 0(0.0)	1.000	24 (8.7) 2 (0.7)	8 (11.1) 0 (0.0)	1.000
90-day mortality	4 (0.3)	1 (5.0)	0.243		1 (1.4)	1.000
50-day monanty	11 (1.3)	1 (0.0)	0.243	7 (2.5)	1 (1.4)	1.000

Table I. Continued

BMI: Body mass index; DM: diabetes mellitus; ASA: American society of anesthesiologists; CEA: carcinoembryonic antigen; CA19-9: Carbohydrate antigen 19-9; PPPD: pylorus preserving pancreaticoduodenectomy; PRPD: pylorus resecting pancreaticoduodenectomy; DP: distal pancreatectomy; TP: total pancreatectomy; EBL: estimated blood loss; LN: lymph node; POPF: postoperative pancreatic fistula; CR-POPF: clinically relevant POPF; UpS: upfront surgery; NAT: neoadjuvant treatment; RPC: resectable pancreatic cancer; LAPC: locally advanced pancreatic cancer. Bold *p*-Values are considered statistically significant (*p*<0.05).

fact that the patients who underwent NAT had a significantly larger tumor at the time of diagnosis. NAT appeared to be effective oncologically in RPC as well, but its significance was poor. The results of short-term postoperative outcomes including general major complications and CR-POPF showed no significant differences between the UpS and the NAT groups in both RPC and LAPC.

The NAT group included 20 cases in RPC, which was quite a lot when compared to 72 cases in LAPC. We believe that because NAT was administered due to PV or SMV invasion, and cases which contact angle of invaded vessel was less than 180°, were classified as RPC according to the NCCN guidelines (20). Since many studies have demonstrated the preferable outcomes of NAT in RPC, it is expected that NAT will be administered to more RPC patients in the future (28-31).

In LAPC, the high rate of combined operation in the UpS group was significant when compared with the NAT group. Most of these cases were subjected to resection of adjacent

	RPC (n=80)			LAPC (n=136)		
	UpS group (n=60)	NAT group (n=20)	<i>p</i> -Value	UpS group (n=68)	NAT group (n=68)	<i>p</i> -Value
Age	64.3±10.0	63.7±8.2	0.799	60.6±9.5	61.1±9.4	0.759
Gender			1.000			1.000
Male	42 (70.0)	14 (70.0)		43 (63.2)	42 (61.8)	
Female	18 (30.0)	6 (30.0)		25 (36.8)	26 (38.2)	
BMI (kg/m ²)	22.8±2.8	23.1±2.8	0.697	23.1±3.3	23.2±3.0	0.863
DM			1.000			0.721
No	21 (35.0)	7 (35.0)		42 (61.8)	45 (66.2)	
Yes	39 (65.0)	13 (65.0)		26 (38.2)	23 (33.8)	
ASA score			0.880			1.000
1	6 (10.0)	2 (10.0)		4 (5.9)	5 (7.4)	
2	50 (83.3)	16 (80.0)		57 (83.8)	57 (83.8)	
3	4 (6.7)	2 (10.0)		7 (10.3)	6 (8.8)	
Initial tumor size (cm)	3.1±1.1	3.2±0.7	0.754	3.1±1.1	3.1±0.9	0.709

Table II. Matching factors after PSM [Mean±Standard deviation/number (percent)].

PSM: Propensity score matching; NAT: neoadjuvant treatment; UpS: upfront surgery; RPC: resectable pancreatic cancer; LAPC: locally advanced pancreatic cancer; BMI: body mass index; DM: diabetes mellitus; ASA: American society of anesthesiologists.

organs involved by a locally advanced tumor. There were also a few cases that combined operation was performed in order to manage an accidently occurring injury, possibly due to a locally advanced tumor.

There was a significant difference in the tendency of vascular resection between RPC and LAPC. The rate of vascular resection was very low in the UpS group in RPC, as expected. It was found that there were more patients whose invaded vessel should be eventually resected during conversion surgery in the NAT group belonging to RPC. On the other hand, in LAPC, when upfront surgery was performed, the rate of resection of the invaded vessel was higher. Also, when NAT was first administered in LAPC, the rate of vascular resection was low; this is an oncologic benefit of NAT (24, 25).

However, this point may be a limitation involving selection bias in our study. There are certainly many NAT cases that did not undergo conversion surgery or were lost. It was very likely that they were more advanced or susceptible to complications due to a generally poor clinical condition. If they had conversion surgery, the rate of vascular resection would have risen considerably, and the short-term postoperative outcomes might also be found to be significantly different when compared with the UpS group.

Because this was a retrospective study and the data were entirely based on medical records of our center, this study has some limitations. There might exist some information that we were not able to collect from the medical records. That is because there must have been patients whose followup was not continuous and lost.

Although there might be these limitations, except for three patients whose drain amylase levels were unmeasured,

almost all of included patients were investigated to determine the occurrence of POPF, a major short-term postoperative complication after pancreatectomy. Because it has been a routine practice to measure drainage amylase levels on the third day after surgery in all patients who underwent any pancreatectomy. Also, it could be stated that data of 30-days mortality and 90-days mortality were accurate since the Department of Medical Records in our center collects information on the fact and date of death from the government departments and includes it in the electronic medical records.

Through this retrospectively descriptive study, we were able to identify the patients who received NAT for PDAC in our high-volume single center. Data on the short-term postoperative outcomes, the purpose of this study, were searched and analyzed. It was confirmed that there were no significant differences between the cases of upfront surgery and the cases of NAT followed by surgery.

Conclusion

In cases where NAT was performed followed by the surgery, the short-term postoperative (90 days) outcomes were comparable to those of upfront surgery cases. We concluded that it is reasonable to perform conversion surgery for PDAC patients who underwent NAT. This can be applied regardless of whether patients are included in resectable, borderline resectable, or unresectable status at the time of PDAC diagnosis.

In the future, we plan to investigate the long-term postoperative outcomes in our center. If it can be confirmed that the long-term outcomes are also favorable in the cases of

	RPC (n=80)			LAPC (n=136)			
	UpS group (n=60)	NAT group (n=20)	<i>p</i> -Value	UpS group (n=68)	NAT group (n=68)	<i>p</i> -Value	
Body weight (kg)	61.5±10.6	62.2±10.1	0.816	61.7±10.6	61.9±9.4	0.951	
Preoperative CEA			0.465			0.730	
Normal (≤5 ng/ml)	42 (70.0)	15 (75.0)		48 (70.6)	49 (72.0)		
Elevated (>5 ng/ml)	8 (13.3)	4 (20.0)		6 (8.8)	8 (11.8)		
Unknown	10 (16.7)	1 (5.0)		14 (20.6)	11 (16.2)		
Preoperative CA19-9			0.363			0.052	
Normal (≤37 U/ml)	20 (33.3)	4 (20.0)		16 (23.5)	25 (36.8)		
Elevated (>37 U/ml)	38 (63.4)	16 (80.0)		49 (72.1)	43 (63.2)		
Unknown	2 (3.3)	0 (0.0)		3 (4.4)	0 (0.0)		
Operation type		· · /	0.240	· · ·		0.363	
PPPD	13 (21.7)	9 (45.0)	01210	29 (42.6)	20 (29.4)	0.000	
PRPD	24 (40.0)	5 (25.0)		23 (33.8)	26 (38.2)		
DP	20 (33.3)	5 (25.0)		11 (16.2)	17 (25.0)		
TP	3 (5.0)	1 (5.0)		5 (7.4)	5 (7.4)		
Vascular resection	5 (5.0)	1 (5.0)	<0.001	5 (7.4)	5 (7.4)	<0.001	
	55 (01 7)	0 (45 0)	<0.001	20 (29.4)	15 (66 2)	<0.001	
No	55 (91.7)	9 (45.0)		· /	45 (66.2)		
Yes	5 (8.3)	11 (55.0)	0.050	48 (70.6)	23 (33.8)	0.004	
Combined operation			0.059		<i></i>	<0.001	
No	50 (83.3)	20 (100.0)		57 (83.8)	68 (100.0)		
Yes	10 (16.7)	0 (0.0)		11 (16.2)	0 (0.0)		
Operation duration (minutes)	287.7±79.2	322.8±72.2	0.083	351.1±89.7	350.1±102.7	0.953	
EBL (ml)	505.8±703.3	1027.5±2202.4	0.109	521.3±317.6	614.7±703.0	0.321	
Differentiation			0.024			0.640	
Well	1 (1.7)	1 (5.0)		4 (5.9)	3 (4.4)		
Moderately	42 (70.0)	17 (85.0)		52 (76.5)	46 (67.6)		
Poorly	17 (28.3)	1 (5.0)		10 (14.7)	14 (20.6)		
Undifferentiated	0 (0.0)	0 (0.0)		0 (0.0)	1 (1.5)		
Unknown	0 (0.0)	1 (5.0)		2 (2.9)	4 (5.9)		
Tumor size	3.2±1.2	2.8±1.0	0.290	3.6±2.0	2.3±1.2	<0.001	
T stage			0.490			<0.001	
Tis	0 (0.0)	0 (0.0)		0 (0.0)	0 (0.0)		
T1a	0 (0.0)	0 (0.0)		1 (1.5)	6 (8.8)		
T1b	0 (0.0)	1 (5.0)		0 (0.0)	4 (5.9)		
T1c	10 (16.7)	3 (15.0)		6 (8.8)	15 (22.0)		
T2	39 (65.0)	13 (65.0)		44 (64.7)	39 (57.4)		
T2 T3	11 (18.3)	3 (15.0)		17 (25.0)	4 (5.9)		
	11 (10.5)	5 (15.0)	0.375	17 (23.0)	4 (3.9)	<0.001	
N stage N0	24 (40.0)	11 (55 0)	0.575	10 (28.0)	16 (67 6)	N0.001	
	× /	11 (55.0)		19 (28.0)	46 (67.6)		
N1	22 (36.7)	7 (35.0)		33 (48.5)	18 (26.5)		
N2	14 (23.3)	2 (10.0)	0.000	16 (23.5)	4 (5.9)	0.001	
Harvested LN	18.2±11.1	18.9±10.5	0.828	22.8±12.5	16.7±8.3	0.001	
Metastatic LN	1.9±2.6	1.4±3.2	0.472	2.9±5.3	0.8±1.8	0.002	
M stage			1.000			1.000	
M0	59 (98.3)	20 (100.0)		67 (98.5)	68 (100.0)		
M1	1 (1.7)	0 (0.0)		1 (1.5)	0 (0.0)		
Resection margin			0.566			0.197	
R0	43 (71.7)	16 (80.0)		46 (67.7)	52 (76.5)		
R1	17 (28.3)	4 (20.0)		20 (29.4)	12 (17.6)		
R2	0 (0.0)	0 (0.0)		2 (2.9)	4 (5.9)		
Lymphovascular invasion			0.578			0.001	
No	20 (33.3)	9 (45.0)		20 (29.4)	40 (58.8)		
Yes	35 (58.4)	9 (45.0)		42 (61.8)	22 (32.4)		
Unknown	5 (8.3)	2 (10.0)		6 (8.8)	6 (8.8)		
Perineural invasion	- ()	· · · · · /	0.697	. ()	. ()	< 0.001	
No	3 (5.0)	2 (10.0)		2 (2.9)	19 (27.9)		
Yes	56 (93.3)	18 (90.0)		64 (94.2)	46 (67.7)		
Unknown	1 (1.7)	0 (0.0)		2 (2.9)	3 (4.4)		

Table III. Clinical, operative, pathological characteristics and short-term postoperative outcomes after PSM [Mean±Standard deviation/number (percent)].

Table III. Continued

Table III. Continued

	RPC (n=80)			LAPC (n=136)		
	UpS group (n=60)	NAT group (n=20)	<i>p</i> -Value	UpS group (n=68)	NAT group (n=68)	<i>p</i> -Value
Length of stay (days)	14.0±11.6	11.6±4.9	0.374	12.6±5.9	12.9±8.4	0.842
Clavien-Dindo classification			0.648			0.065
No complication	33 (55.0)	11 (55.0)		30 (44.1)	37 (54.4)	
Minor						
Ι	2 (3.3)	2 (10.0)		4 (5.9)	6 (8.8)	
II	12 (20.0)	4 (20.0)		18 (26.5)	13 (19.1)	
Major						
IIIa	10 (16.7)	2 (10.0)		15 (22.0)	7 (10.3)	
IIIb	1 (1.7)	1 (5.0)		0 (0.0)	4 (5.9)	
IVa	2 (3.3)	0 (0.0)		0 (0.0)	1 (1.5)	
IVb	0 (0.0)	0 (0.0)		1 (1.5)	0 (0.0)	
V	0 (0.0)	0 (0.0)		0 (0.0)	0 (0.0)	
POPF	n=57	n=19	1.000	n=63	n=63	1.000
No (biochemical leak) CR-POPF	53 (93.0)	18 (94.7)		61 (96.8)	61 (96.8)	
Grade B	3 (5.3)	1 (5.3)		1 (1.6)	2 (3.2)	
Grade C	1 (1.7)	0 (0.0)		1 (1.6)	0 (0.0)	
TP	3	1		5	5	
30-day unplanned readmission	6 (10.0)	1 (5.0)	0.673	6 (8.8)	4 (5.9)	0.744
90-day unplanned readmission	10 (16.7)	1 (5.0)	0.275	8 (11.8)	7 (10.3)	1.000
30-day mortality	0 (0.0)	0 (0.0)	-	0 (0.0)	0 (0.0)	-
90-day mortality	0 (0.0)	1 (5.0)	0.250	0 (0.0)	1 (1.5)	1.000

PSM: Propensity score matching; NAT: neoadjuvant treatment; UpS: upfront surgery; RPC: resectable pancreatic cancer; LAPC: locally advanced pancreatic cancer; CEA: carcinoembryonic antigen; CA19-9: Carbohydrate antigen 19-9; PPPD: pylorus preserving pancreaticoduodenectomy; PRPD: pylorus resecting pancreaticoduodenectomy; DP: distal pancreatectomy; TP: total pancreatectomy; EBL: estimated blood loss; LN: lymph node; POPF: postoperative pancreatic fistula; CR-POPF: clinically relevant POPF. Bold *p*-Values are considered statistically significant (*p*<0.05).

NAT followed by surgery in our high-volume single center, it will contribute to standardize PDAC treatment strategies.

Conflicts of Interest

The Authors declare no conflicts of interest, financial or otherwise, in relation to this study.

Authors' Contributions

Conception/design: Jin Seok Heo, Sang Hyun Shin, and Ji Hye Jung; Provision of study material or patients: Ji Hye Jung, So Kyung Yoon, and Sang Hyun Shin; Collection and assembly of data: Ji Hye Jung, So Jeong Yoon, and In Woong Han; Data analysis and interpretation: Ji Hye Jung, So Kyung Yoon, and Jin Seok Heo; Manuscript writing: Ji Hye Jung, Sang Hyun Shin, and Jin Seok Heo. All Authors have read and approved the final manuscript.

References

 Siegel RL, Miller KD and Jemal A: Cancer statistics, 2020. CA Cancer J Clin *70(1)*: 7-30, 2020. PMID: 31912902. DOI: 10.3322/caac.21590

- 2 Hong S, Won YJ, Park YR, Jung KW, Kong HJ, Lee ES and Community of Population-Based Regional Cancer Registries: Cancer statistics in Korea: Incidence, mortality, survival, and prevalence in 2017. Cancer Res Treat 52(2): 335-350, 2020. PMID: 32178489. DOI: 10.4143/crt.2020.206
- 3 Kumar R, Herman JM, Wolfgang CL and Zheng L: Multidisciplinary management of pancreatic cancer. Surg Oncol Clin N Am 22(2): 265-287, 2013. PMID: 23453334. DOI: 10.1016/j.soc.2012.12.003
- 4 Coveler AL, Herman JM, Simeone DM and Chiorean EG: Localized pancreatic cancer: Multidisciplinary management. Am Soc Clin Oncol Educ Book 35: e217-e226, 2016. PMID: 27249726. DOI: 10.1200/EDBK_160827
- 5 Strobel O, Neoptolemos J, Jäger D and Büchler MW: Optimizing the outcomes of pancreatic cancer surgery. Nat Rev Clin Oncol *16(1)*: 11-26, 2019. PMID: 30341417. DOI: 10.1038/s41571-018-0112-1
- 6 Warschkow R, Widmann B, Beutner U, Marti L, Steffen T, Schiesser M and Schmied BM: The more the better-lower rate of stage migration and better survival in patients with retrieval of 20 or more regional lymph nodes in pancreatic cancer: a population-based propensity score matched and trend SEER analysis. Pancreas 46(5): 648-657, 2017. PMID: 28196023. DOI: 10.1097/MPA.000000000000784

- 7 Ghaneh P, Kleeff J, Halloran CM, Raraty M, Jackson R, Melling J, Jones O, Palmer DH, Cox TF, Smith CJ, O'Reilly DA, Izbicki JR, Scarfe AG, Valle JW, McDonald AC, Carter R, Tebbutt NC, Goldstein D, Padbury R, Shannon J, Dervenis C, Glimelius B, Deakin M, Anthoney A, Lerch MM, Mayerle J, Oláh A, Rawcliffe CL, Campbell F, Strobel O, Büchler MW, Neoptolemos JP and European Study Group for Pancreatic Cancer: The impact of positive resection margins on survival and recurrence following resection and adjuvant chemotherapy for pancreatic ductal adenocarcinoma. Ann Surg 269(3): 520-529, 2019. PMID: 29068800. DOI: 10.1097/SLA.00000000002557
- 8 Michelassi F, Erroi F, Dawson PJ, Pietrabissa A, Noda S, Handcock M and Block GE: Experience with 647 consecutive tumors of the duodenum, ampulla, head of the pancreas, and distal common bile duct. Ann Surg 210(4): 544-54; discussion 554-6, 1989. PMID: 2679459. DOI: 10.1097/00000658-198910000-00015
- 9 Yeo CJ, Sohn TA, Cameron JL, Hruban RH, Lillemoe KD and Pitt HA: Periampullary adenocarcinoma: analysis of 5-year survivors. Ann Surg 227(6): 821-831, 1998. PMID: 9637545. DOI: 10.1097/00000658-199806000-00005
- 10 Cameron JL, Riall TS, Coleman J and Belcher KA: One thousand consecutive pancreaticoduodenectomies. Ann Surg 244(1): 10-15, 2006. PMID: 16794383. DOI: 10.1097/01.sla.0000217673.04165.ea
- 11 Cameron JL and He J: Two thousand consecutive pancreaticoduodenectomies. J Am Coll Surg 220(4): 530-536, 2015. PMID: 25724606. DOI: 10.1016/j.jamcollsurg.2014.12.031
- 12 El Nakeeb A, Askar W, Atef E, Hanafy EE, Sultan AM, Salah T, Shehta A, Sorogy ME, Hamdy E, Hemly ME, El-Geidi AA, Kandil T, Shobari ME, Allah TA, Fouad A, Zeid MA, Eneen AAE, El-Hak NG, Ebidy GE, Fathy O, Sultan A and Wahab MA: Trends and outcomes of pancreaticoduodenectomy for periampullary tumors: A 25-year single-center study of 1000 consecutive cases. World J Gastroenterol 23(38): 7025-7036, 2017. PMID: 29097875. DOI: 10.3748/wjg.v23.i38.7025
- 13 Jung JH, Choi DW, Yoon S, Yoon SJ, Han IW, Heo JS and Shin SH: Three thousand consecutive pancreaticoduodenectomies in a tertiary cancer center: a retrospective observational study. J Clin Med 9(8): 2558, 2020. PMID: 32784559. DOI: 10.3390/jcm9082558
- 14 Tuveson DA and Neoptolemos JP: Understanding metastasis in pancreatic cancer: a call for new clinical approaches. Cell 148(1-2): 21-23, 2012. PMID: 22265397. DOI: 10.1016/j.cell.2011.12.021
- 15 Haeno H, Gonen M, Davis MB, Herman JM, Iacobuzio-Donahue CA and Michor F: Computational modeling of pancreatic cancer reveals kinetics of metastasis suggesting optimum treatment strategies. Cell 148(1-2): 362-375, 2012. PMID: 22265421. DOI: 10.1016/j.cell.2011.11.060
- 16 Springfeld C, Jäger D, Büchler MW, Strobel O, Hackert T, Palmer DH and Neoptolemos JP: Chemotherapy for pancreatic cancer. Presse Med 48(3 Pt 2): e159-e174, 2019. PMID: 30879894. DOI: 10.1016/j.lpm.2019.02.025
- 17 Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, Schramm H, Fahlke J, Zuelke C, Burkart C, Gutberlet K, Kettner E, Schmalenberg H, Weigang-Koehler K, Bechstein WO, Niedergethmann M, Schmidt-Wolf I, Roll L, Doerken B and Riess H: Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 297(3): 267-277, 2007. PMID: 17227978. DOI: 10.1001/jama.297.3.267

- 18 Ueno H, Kosuge T, Matsuyama Y, Yamamoto J, Nakao A, Egawa S, Doi R, Monden M, Hatori T, Tanaka M, Shimada M and Kanemitsu K: A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer. Br J Cancer 101(6): 908-915, 2009. PMID: 19690548. DOI: 10.1038/sj.bjc.6605256
- 19 Hartwig W, Werner J, Jäger D, Debus J and Büchler MW: Improvement of surgical results for pancreatic cancer. Lancet Oncol 14(11): e476-e485, 2013. PMID: 24079875. DOI: 10.1016/S1470-2045(13)70172-4
- 20 Tempero MA, Malafa MP, Al-Hawary M, Asbun H, Bain A, Behrman SW, Benson AB 3rd, Binder E, Cardin DB, Cha C, Chiorean EG, Chung V, Czito B, Dillhoff M, Dotan E, Ferrone CR, Hardacre J, Hawkins WG, Herman J, Ko AH, Komanduri S, Koong A, LoConte N, Lowy AM, Moravek C, Nakakura EK, O'Reilly EM, Obando J, Reddy S, Scaife C, Thayer S, Weekes CD, Wolff RA, Wolpin BM, Burns J and Darlow S: Pancreatic adenocarcinoma, version 2.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 15(8): 1028-1061, 2017. PMID: 28784865. DOI: 10.6004/jnccn.2017.0131
- 21 Mokdad AA, Minter RM, Zhu H, Augustine MM, Porembka MR, Wang SC, Yopp AC, Mansour JC, Choti MA and Polanco PM: Neoadjuvant therapy followed by resection *versus* upfront resection for resectable pancreatic cancer: a propensity score matched analysis. J Clin Oncol 35(5): 515-522, 2017. PMID: 27621388. DOI: 10.1200/JCO.2016.68.5081
- 22 Tzeng CW, Tran Cao HS, Lee JE, Pisters PW, Varadhachary GR, Wolff RA, Abbruzzese JL, Crane CH, Evans DB, Wang H, Abbott DE, Vauthey JN, Aloia TA, Fleming JB and Katz MH: Treatment sequencing for resectable pancreatic cancer: influence of early metastases and surgical complications on multimodality therapy completion and survival. J Gastrointest Surg *18*(*1*): 16-24; discussion 24-5, 2014. PMID: 24241967. DOI: 10.1007/s11605-013-2412-1
- 23 Christians KK, Tsai S, Mahmoud A, Ritch P, Thomas JP, Wiebe L, Kelly T, Erickson B, Wang H, Evans DB and George B: Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer: a new treatment paradigm? Oncologist *19*(*3*): 266-274, 2014. PMID: 24569947. DOI: 10.1634/theoncologist.2013-0273
- 24 Jang JY, Han Y, Lee H, Kim SW, Kwon W, Lee KH, Oh DY, Chie EK, Lee JM, Heo JS, Park JO, Lim DH, Kim SH, Park SJ, Lee WJ, Koh YH, Park JS, Yoon DS, Lee IJ and Choi SH: Oncological benefits of neoadjuvant chemoradiation with gemcitabine *versus* upfront surgery in patients with borderline resectable pancreatic cancer: a prospective, randomized, openlabel, multicenter phase 2/3 trial. Ann Surg 268(2): 215-222, 2018. PMID: 29462005. DOI: 10.1097/SLA.000000000002705
- 25 Yoo C, Shin SH, Kim KP, Jeong JH, Chang HM, Kang JH, Lee SS, Park DH, Song TJ, Seo DW, Lee SK, Kim MH, Park JH, Hwang DW, Song KB, Lee JH, Ryoo BY and Kim SC: Clinical outcomes of conversion surgery after neoadjuvant chemotherapy in patients with borderline resectable and locally advanced unresectable pancreatic cancer: a single-center, retrospective analysis. Cancers (Basel) *11*(*3*): 278, 2019. PMID: 30813624. DOI: 10.3390/cancers11030278
- 26 Michelakos T, Pergolini I, Castillo CF, Honselmann KC, Cai L, Deshpande V, Wo JY, Ryan DP, Allen JN, Blaszkowsky LS, Clark JW, Murphy JE, Nipp RD, Parikh A, Qadan M, Warshaw AL, Hong TS, Lillemoe KD and Ferrone CR: Predictors of

resectability and survival in patients with borderline and locally advanced pancreatic cancer who underwent neoadjuvant treatment with FOLFIRINOX. Ann Surg *269(4)*: 733-740, 2019. PMID: 29227344. DOI: 10.1097/SLA.00000000002600

- 27 Chawla A, Molina G, Pak LM, Rosenthal M, Mancias JD, Clancy TE, Wolpin BM and Wang J: Neoadjuvant therapy is associated with improved survival in borderline-resectable pancreatic cancer. Ann Surg Oncol 27(4): 1191-1200, 2020. PMID: 31802297. DOI: 10.1245/s10434-019-08087-z
- 28 Artinyan A, Anaya DA, McKenzie S, Ellenhorn JD and Kim J: Neoadjuvant therapy is associated with improved survival in resectable pancreatic adenocarcinoma. Cancer *117(10)*: 2044-2049, 2011. PMID: 21523715. DOI: 10.1002/cncr.25763
- 29 Christians KK, Heimler JW, George B, Ritch PS, Erickson BA, Johnston F, Tolat PP, Foley WD, Evans DB and Tsai S: Survival of patients with resectable pancreatic cancer who received neoadjuvant therapy. Surgery 159(3): 893-900, 2016. PMID: 26602840. DOI: 10.1016/j.surg.2015.09.018
- 30 de Geus SW, Evans DB, Bliss LA, Eskander MF, Smith JK, Wolff RA, Miksad RA, Weinstein MC and Tseng JF: Neoadjuvant therapy versus upfront surgical strategies in resectable pancreatic cancer: A Markov decision analysis. Eur J Surg Oncol 42(10): 1552-1560, 2016. PMID: 27570116. DOI: 10.1016/j.ejso.2016.07.016
- 31 Seufferlein T and Ettrich TJ: Treatment of pancreatic cancerneoadjuvant treatment in resectable pancreatic cancer (PDAC). Transl Gastroenterol Hepatol 4: 21, 2019. PMID: 30976724. DOI: 10.21037/tgh.2019.03.05
- 32 Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, Meyer L, Gress DM, Byrd DR and Winchester DP: The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging. CA Cancer J Clin 67(2): 93-99, 2017. PMID: 28094848. DOI: 10.3322/caac.21388
- 33 Campbell F, Smith RA, Whelan P, Sutton R, Raraty M, Neoptolemos JP and Ghaneh P: Classification of R1 resections for pancreatic cancer: the prognostic relevance of tumour involvement within 1 mm of a resection margin. Histopathology 55(3): 277-283, 2009. PMID: 19723142. DOI: 10.1111/j.1365-2559.2009.03376.x

- 34 Verbeke CS, Leitch D, Menon KV, McMahon MJ, Guillou PJ and Anthoney A: Redefining the R1 resection in pancreatic cancer. Br J Surg 93(10): 1232-1237, 2006. PMID: 16804874. DOI: 10.1002/bjs.5397
- 35 Karim SAM, Abdulla KS, Abdulkarim QH and Rahim FH: The outcomes and complications of pancreaticoduodenectomy (Whipple procedure): Cross sectional study. Int J Surg 52: 383-387, 2018. PMID: 29438817. DOI: 10.1016/j.ijsu.2018.01.041
- 36 Bolliger M, Kroehnert JA, Molineus F, Kandioler D, Schindl M and Riss P: Experiences with the standardized classification of surgical complications (Clavien-Dindo) in general surgery patients. Eur Surg 50(6): 256-261, 2018. PMID: 30546385. DOI: 10.1007/s10353-018-0551-z
- 37 Pulvirenti A, Ramera M and Bassi C: Modifications in the International Study Group for Pancreatic Surgery (ISGPS) definition of postoperative pancreatic fistula. Transl Gastroenterol Hepatol 2: 107, 2017. PMID: 29354764. DOI: 10.21037/tgh.2017.11.14
- 38 Bertens KA, Crown A, Clanton J, Alemi F, Alseidi AA, Biehl T, Helton WS and Rocha FG: What is a better predictor of clinically relevant postoperative pancreatic fistula (CR-POPF) following pancreaticoduodenectomy (PD): postoperative day one drain amylase (POD1DA) or the fistula risk score (FRS)? HPB (Oxford) 19(1): 75-81, 2017. PMID: 27825541. DOI: 10.1016/ j.hpb.2016.10.001
- 39 Lin Z, Tang B, Cai J, Wang X, Li C, Tian X, Yang Y and Wang X: Preoperative prediction of clinically relevant postoperative pancreatic fistula after pancreaticoduodenectomy. Eur J Radiol *139*: 109693, 2021. PMID: 33857829. DOI: 10.1016/j.ejrad.2021.109693

Received June 23, 2021 Revised October 5, 2021 Accepted October 6, 2021